Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study-Reference-Cited by-同舟云学术

Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study

Published:2019-12-01 Issue:4 Volume:6 Page:MMT31
ISSN:2045-0885
Container-title:Melanoma Management
language:en
Short-container-title:Melanoma Management

Author:

Shah Shweta¹,Raskin Leon²,Cohan David³,Hamid Omid⁴,Freeman Morganna L⁵

Affiliation:

1. Global Health Economics, Amgen Inc., Thousand Oaks, CA, USA

2. Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA

3. Medical Affairs, Amgen Inc., Thousand Oaks, CA, USA

4. The Angeles Clinic & Research Institute, Los Angeles, CA, USA

5. City of Hope, Duarte, CA, USA

Abstract

Aim: To describe treatment changes from 2011 to 2017 and demographic/clinical characteristics of patients with advanced melanoma who received systemic therapy by BRAF status. Patients & methods: Treatment patterns were evaluated in adults from the Oncology Services Comprehensive Electronic Records database who received antimelanoma systemic therapy. Results: Checkpoint inhibitors were prevailingly prescribed (66%); usage increased from 2011 (21%) to 2017 (84%). BRAF/MEK inhibitors were the second most common (21%); usage increased from 2011 (6%) to 2012 (18%) and stabilized until 2017 (22%). BRAF/MEK inhibitors (65%) and checkpoint inhibitors (57%) were predominantly used for BRAFMut melanoma. Conclusion: Overall, checkpoint inhibitors have supplanted other therapies for advanced melanoma. Treatment shifts have occurred for BRAFMut melanoma, notably increased use of checkpoint inhibitors and BRAF/MEK combinations compared with monotherapies.

Publisher

Future Medicine Ltd

Subject

Dermatology,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/mmt-2019-0013

Reference29 articles.

1. National Institutes of Health, National Cancer Institute. SEER cancer stat facts: melanoma of the skin 2018 (2019). https://seer.cancer.gov/statfacts/html/melan.html.

2. American Cancer Society. Cancer facts & figures 2016 (2018). https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf.

3. Melanoma treatment in review

4. Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma

5. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015–2018 in Greece. The ‘SUMMER’ study: a retrospective multicenter chart review project;Melanoma Research;2023-12-13

2. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future;Clinical Cancer Research;2023-01-10

3. Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma;Melanoma Research;2022-01-17